Abstract: Anti-CD47 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer, inflammatory disease, infectious disease, atherosclerosis, cardiovascular disease, metabolic disease, radiation-induced injury, and/or autoimmune disease.

Abstract: Anti-LAG-3 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer, an inflammatory disease, an autoimmune disease, type 1 diabetes, and/or infectious diseases.

Abstract: The present invention relates to the technical field of optical communications, and particularly relates to a wavelength locking optical module, a device, and a wavelength locking method. The optical module comprises a DSP unit, a TOSA, and a ROSA. The DSP unit has a signal output terminal connected to the TOSA and a signal input terminal connected to the ROSA. A TEC is provided within the TOSA, and is used to adjust a temperature according to a control signal sent from the DSP unit and accordingly adjust a emission wavelength of the TOSA. An optical filter is provided within the ROSA and used to filter a wave, such that light having a pre-determined wavelength passes through the filter and is converted into an electrical signal and output to the DSP unit. The DSP unit calculates an optical power according to the received electrical signal, and determines wavelength control of the TOSA according to an optical power change.

Abstract: The present invention provides methods for detecting and/or treating a subject having an aneurysm or at risk for developing an aneurysm. It has been discovered that a key metabolite of the kynurenine (Kyn) pathway, a major route for the metabolism of essential amino acid tryptophan (Trp) into nicotinamide adenine dinucleotide (NAD+), plays a critical role in the formation of aneurysms, for example abdominal aortic aneurysms. In particular, it has been discovered that 3-Hydroxyanthranilic acid (3-HAA), a product of kynureninase (KYNU), plays a causative role in the formation of aneurysms by, for example exerting pro-inflammatory effects on vascular smooth muscle cells. It has further been discovered that elevated levels of 3-HAA are indicative of the presence and/or progression of an aneurysm, and 3-HAA levels correlate with the size (aortic diameter) of the aneurysm.

Abstract: Anti-apelin antibodies and antigen-binding fragments thereof are described.

Abstract: Chimeric antigen receptors (CARs) specific to CLDN18.2, vectors encoding the CLDN18.2 CAR, recombinant host cells comprising the CLDN18.2 CAR (CAR-Ts or CAR-NKs), and methods of using the CAR-Ts or CAR-NKs to treat a disease associated with the expression of CLDN18.2 thereof are described.

Abstract: Chimeric antigen receptors (CARs) specific to DLL3, vectors encoding the DLL3 CAR, recombinant host cells comprising the DLL3 CAR (CAR-Ts or CAR-NKs), and methods of using the CAR-Ts or CAR-NKs to treat a disease associated with the expression of DLL3 thereof are described.

Abstract: Chimeric antigen receptors (CARs) specific to FOLR1, vectors encoding the FOLR1 CAR, recombinant host cells comprising the FOLR1 CAR (CAR-Ts or CAR-NKs), and methods of using the CAR-Ts or CAR-NKs to treat a disease associated with the expression of FOLR1 thereof are described. Humanized anti-FOLR1 monoclonal antibodies and antigen-binding fragments thereof are also described.

Abstract: Anti-TIP-1 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as cancer.

Abstract: Anti-CD73 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer.

Abstract: Anti-TIM-3 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer, an inflammatory disease, an autoimmune disease, a metabolic disease, and/or infectious diseases.

Abstract: An augmented reality gaming system uses a gameplay device to removably secure a mobile device. The gameplay device has at least one user interface and a wireless transceiver for communicating with the mobile device. An augmented reality gaming app stored in the memory of the mobile device utilizes an image sensor of the mobile device to display a live image on a screen of the mobile device, and causes graphics corresponding to one or more virtual targets to be overlaid on the live image. Using information from a location sensor and an orientation sensor of the mobile device, together with information about a virtual location of the virtual target, the mobile device determines whether a virtual shot triggered by the at least one user interface causes virtual damage to the virtual target.

Abstract: The present invention relates to a technical field of optical communications. It relates to a dual-rate DML device and module, and a calibration method, and in particular, to a dual-rate DML device and module having a built-in signal calibration circuit, and a calibration method. According to the present invention, the signal calibration circuit is added into the device; a PD is prepositioned by means of a novel light splitting structure; a control structure for a sequence-divided multi-channel serial signal is utilized to feed back a monitoring signal to an electric driver to adjust drive current; crosstalk between backlight monitoring is reduced; and high-quality signal output under dual modulation frequencies of 25 Gbps and 28 Gbps is realized.

Abstract: Anti-DLL3 antibodies and antigen-binding fragments thereof, anti-CD47 antibodies and antigen-binding fragments thereof, and anti-CD47/DLL3 bispecific antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases, such as cancer and/or associated complications.

Abstract: Anti-LAG-3 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer, an inflammatory disease, an autoimmune disease, type 1 diabetes, and/or infectious diseases.

Abstract: Anti-TIM-3 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer, an inflammatory disease, an autoimmune disease, a metabolic disease, and/or infectious diseases.

Abstract: Anti-FOLR1 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as cancer.